SEARCH

SEARCH BY CITATION

References

  • 1
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010.
  • 2
    Kitchener HC, Castle PE, Cox JT. Chapter 7: achievements and limitations of cervical cytology screening. Vaccine 2006;24(Suppl 3):S6370.
  • 3
    Cervix Cancer Screening. 10. IARC Press. IARC Handbooks of Cancer Prevention; 2005.
  • 4
    Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007;298:74353.
  • 5
    FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:191527.
  • 6
    Sritipsukho P, Thaweekul Y. Accuracy of visual inspection with acetic acid (VIA) for cervical cancer screening: a systematic review. J Med Assoc Thai 2010;93(Suppl 7):S25461.
  • 7
    Arbyn M, Sankaranarayanan R, Muwonge R, Keita N, Dolo A, Mbalawa CG, et al. Pooled analysis of the accuracy of five cervical cancer screening tests assessed in eleven studies in Africa and India. Int J Cancer 2008;123:15360.
  • 8
    Sankaranarayanan R, Basu P, Wesley RS, Mahe C, Keita N, Mbalawa CC, et al. Accuracy of visual screening for cervical neoplasia: results from an IARC multicentre study in India and Africa. Int J Cancer 2004;110:90713.
  • 9
    Sankaranarayanan R, Esmy PO, Rajkumar R, Muwonge R, Swaminathan R, Shanthakumari S, et al. Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet 2007;370:398406.
  • 10
    Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009;360:138594.
  • 11
    Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:129.
  • 12
    Sankaranarayanan R, Wesley RS, editors. A Practical Manual on Visual Screening for Cervical Neoplasia, Vol. 41. Lyon, France: IARC Press. IARC Technical Publication; 2003.
  • 13
    Pretorius RG, Zhang WH, Belinson JL, Huang MN, Wu LY, Zhang X, et al. Colposcopically directed biopsy, random cervical biopsy, and endocervical curettage in the diagnosis of cervical intraepithelial neoplasia II or worse. Am J Obstet Gynecol 2004;191:4304.
  • 14
    Qiao YL, Sellors JW, Eder PS, Bao YP, Lim JM, Zhao FH, et al. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol 2008;9:92936.
  • 15
    Gage JC, Ajenifuja KO, Wentzensen N, Adepiti AC, Stoler M, Eder PS, et al. Effectiveness of a simple rapid human papillomavirus DNA test in rural Nigeria. Int J Cancer 2012;131:29039.
  • 16
    Zhao FH, Lin MJ, Chen F, Hu SY, Zhang R, Belinson JL, et al. Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China. Lancet Oncol 2010;11:116071.
  • 17
    Gravitt PE, Burk RD, Lorincz A, Herrero R, Hildesheim A, Sherman ME, et al. A comparison between real-time polymerase chain reaction and hybrid capture 2 for human papillomavirus DNA quantitation. Cancer Epidemiol Biomarkers Prev 2003;12:47784.
  • 18
    Cuzick J. A Wilcoxon-type test for trend. Stat Med 1985;4:8790.
  • 19
    Sahasrabuddhe VV, Bhosale RA, Kavatkar AN, Nagwanshi CA, Joshi SN, Jenkins CA, et al. Comparison of visual inspection with acetic acid and cervical cytology to detect high-grade cervical neoplasia among HIV-infected women in India. Int J Cancer 2012;130:23440.
  • 20
    Sankaranarayanan R, Nessa A, Esmy PO, Dangou JM. Visual inspection methods for cervical cancer prevention. Best Pract Res Clin Obstet Gynaecol 2012;26:22132.
  • 21
    Pretorius RG, Kim RJ, Belinson JL, Elson P, Qiao YL. Inflation of sensitivity of cervical cancer screening tests secondary to correlated error in colposcopy. J Low Genit Tract Dis 2006;10:59.
  • 22
    Hawes SE, Critchlow CW, Faye Niang MA, Diouf MB, Diop A, Toure P, et al. Increased risk of high-grade cervical squamous intraepithelial lesions and invasive cervical cancer among african women with human immunodeficiency virus Type 1 and 2 infections. J Infect Dis 2003;188:55563.
  • 23
    Luchters SM, Vanden Broeck D, Chersich MF, Nel A, Delva W, Mandaliya K, et al. Association of HIV infection with distribution and viral load of HPV types in Kenya: a survey with 820 female sex workers. BMC Infect Dis 2010;10:18.
  • 24
    Vedantham H, Silver MI, Kalpana B, Rekha C, Karuna BP, Vidyadhari K, et al. Determinants of VIA (Visual Inspection of the Cervix After Acetic Acid Application) positivity in cervical cancer screening of women in a peri-urban area in Andhra Pradesh, India. Cancer Epidemiol Biomarkers Prev 2010;19:137380.
  • 25
    Cremer M, Conlisk E, Maza M, Bullard K, Peralta E, Siedhoff M, et al. Adequacy of visual inspection with acetic acid in women of advancing age. Int J Gynaecol Obstet 2011;113:6871.
  • 26
    Pantanowitz L, Hornish M, Cao QJ, Goulart RA. HPV data can be used as a cytopathology laboratory quality indicator. Diagn Cytopathol 2010;38:15960.
  • 27
    Sherman ME, Schiffman MH, Lorincz AT, Manos MM, Scott DR, Kuman RJ, et al. Toward objective quality assurance in cervical cytopathology. Correlation of cytopathologic diagnoses with detection of high-risk human papillomavirus types. Am J Clin Pathol 1994;102:1827.
  • 28
    Zuna RE, Moore W, Dunn ST. HPV DNA testing of the residual sample of liquid-based Pap test: utility as a quality assurance monitor. Mod Pathol 2001;14:14751.